Avidity Biosciences Other Current Liabilities

Avidity Biosciences (RNA) currently reports a other current liabilities of $17M as of June 2026. That compares with $110M in the prior-year period — down 84.8% year over year. Use the charts on this page to explore Avidity Biosciences's other current liabilities history and peer comparisons.

Avidity Biosciences's other current liabilities decreased from $110M to $17M — a 84.8% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Avidity Biosciences reported $17M in other current liabilities as of June 2026. That compares with $110M in the prior-year period — down 84.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current liabilities of $17M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Avidity Biosciences, and consider following RNA for alerts when major investors trade the stock.

Avidity Biosciences is classified in the Healthcare sector. On other current liabilities, it currently shows $17M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RNA with unrelated industries.